Treating triple-negative breast cancer in people with inherited BRCA1 or BRCA2 mutations

https://www.facingourrisk.org/XRAY/treating-triple-negative-breast-cancer-with-BRCA-mutations

Full article: https://sabcs.org/events/2025/rapid-fire-5/

This review summarizes two studies highlighted during the 2025 San Antonio Breast Cancer Symposium. Both studies focus on targeted therapy and immunotherapy given before surgery to treat early-stage triple-negative breast cancer in people with inherited BRCA1 or BRCA2 mutations. One study evaluated pre-surgery treatment with Zejula and Jemperli; the other study evaluated Lynparza and Imfinzi. (posted 2/3/26)

Questions To Ask Your Health Care Provider

What are the potential risks and benefits associated with my recommended therapy?
Do you recommend treatment before surgery? If so, what kind?
Are clinical trials of this combined therapy before surgery underway? Do I qualify for enrollment?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.